Ferdy J. Lejeune

10.1k total citations · 2 hit papers
119 papers, 7.3k citations indexed

About

Ferdy J. Lejeune is a scholar working on Molecular Biology, Oncology and Immunology. According to data from OpenAlex, Ferdy J. Lejeune has authored 119 papers receiving a total of 7.3k indexed citations (citations by other indexed papers that have themselves been cited), including 57 papers in Molecular Biology, 51 papers in Oncology and 43 papers in Immunology. Recurrent topics in Ferdy J. Lejeune's work include Immunotherapy and Immune Responses (36 papers), Cutaneous Melanoma Detection and Management (27 papers) and Melanoma and MAPK Pathways (17 papers). Ferdy J. Lejeune is often cited by papers focused on Immunotherapy and Immune Responses (36 papers), Cutaneous Melanoma Detection and Management (27 papers) and Melanoma and MAPK Pathways (17 papers). Ferdy J. Lejeune collaborates with scholars based in Switzerland, Belgium and Netherlands. Ferdy J. Lejeune's co-authors include Danielle Líénard, Jean‐Charles Cerottini, Daniel E. Speiser, Curzio Rüegg, Pedro Romero, Donata Rimoldi, Patricia Ewalenko, Mikäel J. Pittet, Danila Valmori and Nathalie Renard and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Investigation and Nature Medicine.

In The Last Decade

Ferdy J. Lejeune

117 papers receiving 7.1k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma.

1992 571 citations D Liénard, Patricia Ewalenko et al. Journal of Clinical Oncology profile →
Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909

2005 514 citations Daniel E. Speiser, Danielle Líénard et al. Journal of Clinical Investigation profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ferdy J. Lejeune Switzerland	44	3.3k	3.2k	2.6k	1.0k	566	119	7.3k
Nam H. Dang United States	49	4.2k 1.3×	1.7k 0.5×	2.2k 0.8×	662 0.6×	788 1.4×	194	7.6k
René González United States	48	6.6k 2.0×	2.6k 0.8×	4.4k 1.6×	1.2k 1.1×	729 1.3×	189	9.2k
Albert F. LoBuglio United States	54	2.9k 0.9×	3.0k 0.9×	3.6k 1.4×	1.1k 1.1×	649 1.1×	189	9.5k
Megan S. Lim United States	47	2.8k 0.9×	1.5k 0.5×	3.0k 1.1×	757 0.7×	1.0k 1.8×	230	8.2k
Ronald C. DeConti United States	43	3.8k 1.2×	1.3k 0.4×	2.0k 0.7×	961 0.9×	403 0.7×	92	7.1k
Fathia Mami‐Chouaib France	47	3.7k 1.1×	4.8k 1.5×	2.2k 0.8×	542 0.5×	1.2k 2.2×	107	7.9k
Robert Zeiser Germany	56	2.8k 0.9×	5.2k 1.6×	2.8k 1.1×	805 0.8×	758 1.3×	287	11.4k
Alessandro D. Santin United States	53	4.6k 1.4×	2.4k 0.7×	3.2k 1.2×	1.5k 1.5×	1.4k 2.4×	353	10.6k
Peiguo Chu United States	49	3.5k 1.1×	1.1k 0.3×	2.7k 1.0×	2.0k 1.9×	1.4k 2.5×	151	8.6k
Alessandro Pileri Italy	44	3.2k 1.0×	1.9k 0.6×	2.1k 0.8×	307 0.3×	243 0.4×	335	8.2k

Countries citing papers authored by Ferdy J. Lejeune

Since Specialization

Citations

This map shows the geographic impact of Ferdy J. Lejeune's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ferdy J. Lejeune with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ferdy J. Lejeune more than expected).

Fields of papers citing papers by Ferdy J. Lejeune

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ferdy J. Lejeune. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ferdy J. Lejeune. The network helps show where Ferdy J. Lejeune may publish in the future.

Co-authorship network of co-authors of Ferdy J. Lejeune

This figure shows the co-authorship network connecting the top 25 collaborators of Ferdy J. Lejeune. A scholar is included among the top collaborators of Ferdy J. Lejeune based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ferdy J. Lejeune. Ferdy J. Lejeune is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Robert, Caroline, Célèste Lebbé, Thierry Lesimple, et al.. (2022). Phase I Study of Androgen Deprivation Therapy in Combination with Anti–PD-1 in Melanoma Patients Pretreated with Anti–PD-1. Clinical Cancer Research. 29(5). 858–865. 15 indexed citations

2.

Speiser, Daniel E., Danielle Líénard, Nathalie Rufer, et al.. (2005). Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. Journal of Clinical Investigation. 115(3). 739–746. 36 indexed citations

3.

Speiser, Daniel E., Danielle Líénard, Nathalie Rufer, et al.. (2005). Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. Journal of Clinical Investigation. 115(3). 739–746. 514 indexed citations breakdown →

4.

Rüegg, Curzio, Meriem Hasmim, Ferdy J. Lejeune, & Gian Carlo Alghisi. (2005). Antiangiogenic peptides and proteins: From experimental tools to clinical drugs. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 1765(2). 155–177. 56 indexed citations

5.

Zippelius, Alfred, Pascal Batard, Verena Rubio‐Godoy, et al.. (2004). Effector Function of Human Tumor-Specific CD8 T Cells in Melanoma Lesions: A State of Local Functional Tolerance. Cancer Research. 64(8). 2865–2873. 297 indexed citations

6.

Speiser, Daniel E., Mikäel J. Pittet, Donata Rimoldi, et al.. (2003). Evaluation of melanoma vaccines with molecularly defined antigens by ex vivo monitoring of tumor-specific T cells. Seminars in Cancer Biology. 13(6). 461–472. 45 indexed citations

7.

Lejeune, Ferdy J.. (2002). Clinical use of TNF revisited: improving penetration of anti-cancer agents by increasing vascular permeability. Journal of Clinical Investigation. 110(4). 433–435. 46 indexed citations

8.

Lejeune, Ferdy J.. (2002). Clinical use of TNF revisited: improving penetration of anti-cancer agents by increasing vascular permeability. Journal of Clinical Investigation. 110(4). 433–435. 1 indexed citations

9.

Speiser, Daniel E., Marco Migliaccio, Mikäel J. Pittet, et al.. (2001). Human CD8+ T cells expressing HLA-DR and CD28 show telomerase activity and are distinct from cytolytic effector T cells. European Journal of Immunology. 31(2). 459–466. 39 indexed citations

10.

Suciu, Stefan, Huub Straatman, Alexander M.M. Eggermont, et al.. (2000). High tPA-expression in primary melanoma of the limb correlates with good prognosis. British Journal of Cancer. 83(10). 1351–1359. 37 indexed citations

11.

Valmori, Danila, Valérie Dutoit, Danielle Líénard, et al.. (2000). Tetramer-Guided Analysis of TCR β-Chain Usage Reveals a Large Repertoire of Melan-A-Specific CD8+ T Cells in Melanoma Patients. The Journal of Immunology. 165(1). 533–538. 78 indexed citations

12.

Rimoldi, Donata, Verena Rubio‐Godoy, Valérie Dutoit, et al.. (2000). Efficient Simultaneous Presentation of NY-ESO-1/LAGE-1 Primary and Nonprimary Open Reading Frame-Derived CTL Epitopes in Melanoma. The Journal of Immunology. 165(12). 7253–7261. 71 indexed citations

13.

Lejeune, Ferdy J.. (1999). Actualités sur les mélanomes. Bulletin du Cancer. 86(1). 47–51. 1 indexed citations

14.

D’Souza, Sushila, Donata Rimoldi, Danielle Líénard, et al.. (1998). Circulating MELAN-A/MART-1 specific cytolytic T lymphocyte precursors in HLA-A2+ melanoma patients have a memory phenotype. International Journal of Cancer. 78(6). 699–706. 52 indexed citations

15.

Yilmaz, Aysim, Grégory Bieler, Olivier Spertini, Ferdy J. Lejeune, & Curzio Rüegg. (1998). Pulse treatment of human vascular endothelial cells with high doses of tumor necrosis factor and interferon‐gamma results in simultaneous synergistic and reversible effects on proliferation and morphology. International Journal of Cancer. 77(4). 592–599. 2 indexed citations

16.

Vaglini, Maurizio, et al.. (1997). Value of prophylactic isolated limb perfusion (ILP) for stage I high risk malignant melanoma. Melanoma Research. 7(Supplement 1). S34–S34. 3 indexed citations

17.

Lejeune, Ferdy J.. (1995). High dose recombinant tumour necrosis factor (rTNFα) administered by isolation perfusion for advanced tumours of the limbs: a model for biochemotherapy of cancer. European Journal of Cancer. 31(6). 1009–1016. 63 indexed citations

18.

Liénard, D, et al.. (1992). High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma.. Journal of Clinical Oncology. 10(1). 52–60. 571 indexed citations breakdown →

19.

Mey, Albert De, et al.. (1992). Neonatal Treatment of Giant Naevi. Dermatology. 185(4). 300–301. 11 indexed citations

20.

Ewalenko, Patricia, et al.. (1984). Production of the effector molecule thymidine by human lung alveolar macrophages. European Journal of Cancer and Clinical Oncology. 20(12). 1543–1548. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact